TY - JOUR
T1 - European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
AU - Weller, Michael
AU - van den Bent, Martin
AU - Tonn, Jörg C.
AU - Stupp, Roger
AU - Preusser, Matthias
AU - Cohen-Jonathan-Moyal, Elizabeth
AU - Henriksson, Roger
AU - Rhun, Emilie Le
AU - Balana, Carmen
AU - Chinot, Olivier
AU - Bendszus, Martin
AU - Reijneveld, Jaap C.
AU - Dhermain, Frederick
AU - French, Pim
AU - Marosi, Christine
AU - Watts, Colin
AU - Oberg, Ingela
AU - Pilkington, Geoffrey
AU - Baumert, Brigitta G.
AU - Taphoorn, Martin J.B.
AU - Hegi, Monika
AU - Westphal, Manfred
AU - Reifenberger, Guido
AU - Soffietti, Riccardo
AU - Wick, Wolfgang
PY - 2017/6/1
Y1 - 2017/6/1
N2 - The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas. The guideline is based on the 2016 WHO classification of tumours of the central nervous system and on scientific developments since the 2014 guideline. The recommendations focus on pathological and radiological diagnostics, and the main treatment modalities of surgery, radiotherapy, and pharmacotherapy. In this guideline we have also integrated the results from contemporary clinical trials that have changed clinical practice. The guideline aims to provide guidance for diagnostic and management decisions, while limiting unnecessary treatments and costs. The recommendations are a resource for professionals involved in the management of patients with glioma, for patients and caregivers, and for health-care providers in Europe. The implementation of this guideline requires multidisciplinary structures of care, and defined processes of diagnosis and treatment.
AB - The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas. The guideline is based on the 2016 WHO classification of tumours of the central nervous system and on scientific developments since the 2014 guideline. The recommendations focus on pathological and radiological diagnostics, and the main treatment modalities of surgery, radiotherapy, and pharmacotherapy. In this guideline we have also integrated the results from contemporary clinical trials that have changed clinical practice. The guideline aims to provide guidance for diagnostic and management decisions, while limiting unnecessary treatments and costs. The recommendations are a resource for professionals involved in the management of patients with glioma, for patients and caregivers, and for health-care providers in Europe. The implementation of this guideline requires multidisciplinary structures of care, and defined processes of diagnosis and treatment.
UR - http://www.scopus.com/inward/record.url?scp=85018781033&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S1470-2045(17)30194-8
DO - https://doi.org/10.1016/S1470-2045(17)30194-8
M3 - Review article
C2 - 28483413
SN - 1470-2045
VL - 18
SP - e315-e329
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 6
ER -